Payment overview · 2025
General Payments
$120.78
6 reported records · 4 companies
Healthcare provider profile · identity verified
Randy Curtis Fullerton, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NASHVILLE, TN · NPI 1356325237
Verified facts
What the public records show
CMS Open Payments records show Randy Curtis Fullerton, M.D. received $120.78 in general payments during 2025 across 6 reported records.
AstraZeneca Pharmaceuticals LP accounted for 44.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $53.37 | 44.2% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.67 | 19.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.38 | 19.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.36 | 16.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $120.78 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $35.96 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $23.38 | 1 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
57 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 524 | 146 |
| Alprazolam | Alprazolam | 428 | 64 |
| Gabapentin | Gabapentin | 256 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 243 | 36 |
| Amlodipine Besylate | Amlodipine Besylate | 237 | 63 |
| Metformin Hcl | Metformin Hcl | 222 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 219 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 213 | 63 |
| Glimepiride | Glimepiride | 194 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 185 | 46 |
| Lisinopril | Lisinopril | 178 | 53 |
| Losartan Potassium | Losartan Potassium | 178 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 178 | 45 |
| Azithromycin | Azithromycin | 166 | 113 |
| Meloxicam | Meloxicam | 148 | 56 |
| Simvastatin | Simvastatin | 133 | 36 |
| Atenolol | Atenolol | 128 | 41 |
| Omeprazole | Omeprazole | 113 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 22 |
| Furosemide | Furosemide | 98 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 98 | 28 |
| Donepezil Hcl | Donepezil Hcl | 96 | 21 |
| Cephalexin | Cephalexin | 93 | 58 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 92 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 92 | 30 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 90 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 88 | 31 |
| Allopurinol | Allopurinol | 87 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 84 | 23 |
| Ezetimibe | Ezetimibe | 81 | 25 |
| Tramadol Hcl | Tramadol Hcl | 79 | 12 |
| Ozempic | Semaglutide | 77 | 12 |
| Methylprednisolone | Methylprednisolone | 76 | 61 |
| Sertraline Hcl | Sertraline Hcl | 76 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 75 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 73 | 22 |
| Famotidine | Famotidine | 72 | 26 |
| Amoxicillin | Amoxicillin | 71 | 40 |
| Eliquis | Apixaban | 70 | 12 |
| Dexamethasone | Dexamethasone | 68 | 56 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 67 | 21 |
| Clonidine Hcl | Clonidine Hcl | 64 | 24 |
| Farxiga | Dapagliflozin Propanediol | 57 | 12 |
| Synthroid | Levothyroxine Sodium | 55 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 16 |
| Trulicity | Dulaglutide | 54 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | suppressed |
| Bupropion Xl | Bupropion Hcl | 52 | 17 |
| Pregabalin | Pregabalin | 52 | suppressed |
| Fluconazole | Fluconazole | 50 | 24 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 49 | 13 |
| Trazodone Hcl | Trazodone Hcl | 48 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 31 |
| Nifedipine Er | Nifedipine | 47 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | suppressed |
| Clonazepam | Clonazepam | 43 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 43 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 13 |
| Levofloxacin | Levofloxacin | 41 | 32 |
| Prednisone | Prednisone | 41 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | suppressed |
| Ibuprofen | Ibuprofen | 38 | 14 |
| Indapamide | Indapamide | 38 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | 11 |
| Montelukast Sodium | Montelukast Sodium | 36 | suppressed |
| Carvedilol | Carvedilol | 35 | 12 |
| Finasteride | Finasteride | 34 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 31 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Estradiol | Estradiol | 30 | 11 |
| Olanzapine | Olanzapine | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 29 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 25 |
| Acyclovir | Acyclovir | 28 | 14 |
| Cefuroxime | Cefuroxime Axetil | 28 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 19 |
| Diazepam | Diazepam | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Potassium Chloride | Potassium Chloride | 27 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 18 |
| Baclofen | Baclofen | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Mupirocin | Mupirocin | 26 | 18 |
| Naproxen | Naproxen | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Jardiance | Empagliflozin | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Calcium Acetate | Calcium Acetate | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $120.78 · 6 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Kerendia, Repatha, TRELEGY ELLIPTA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error